Topically applied AHAs and PHAs have transformed many aspects of cosmetic and therapeutic skincare since their discovery for use on skin in 1998. The compounds - first used by dermatologists to alleviate severe scaling associated with the disfiguring skin condition ichthyosis - have consistently proven useful to dermatologists in the treatment of a variety of conditions when used alone, or in combination with other therapeutic regimens.
Clearasil Ultra Treatment Cream combines 10 per cent Benzoyl Peroxide - to eliminate acne-causing bacteria - and Glycolic Acid, a patented amphoteric complex to enable quick exfoliation to reduce skin irritation. The formulation also includes Dimethicone, a skin conditioning agent to soften dry skin.
NeoStrata and Boots Healthcare USA signed the agreement for the formulation and development of Clearasil products - the leading brand in OTC acne treatment - in the second quarter of last year.
NeoStrata is a research-based dermatological company. It holds 120 patents, many licensed by pharmaceutical and cosmetic companies. The company also markets prestige retail brands including Exuviance skin care and CoverBlend by Exuviance, a line of medically developed, concealing treatment cosmetics to correct all types of visible skin imperfections.